38 results about "Bacillus anthrax" patented technology

The invention provides a heterogeneous immunoassay for detection of antibodies and antigens based on specific antigen-antibody immune complex formation with multiple antigen-bearing conjugate components. The invention further provides means for optimizing the assay format for the detection of both low and high-affinity antibodies, and provides means for quantitative detection of both antibody and the corresponding antigen present in a sample. In preferred embodiments, the invention can be practiced to detect presence in biological fluid samples of antibodies to Bacillus anthracis related antigens.

The invention is related to polynucleotide-based anthrax vaccines. In particular, the invention is plasmids operably encoding Bacillus anthracis antigens, in which the naturally-occurring coding regions for the B. anthracis antigens have been modified for improved translation in human or other mammalian cells through codon optimization. In certain embodiments, the coding regions are also modified so as to remove potential N-linked glycosylation sites. B. anthracis antigens which are useful in the invention include, but are not limited to protective antigen (PA), lethal factor (LF), and fragments, variants or derivatives of either of these antigens. The invention is further directed to methods to induce an immune response to B. anthracis in a mammal, for example, a human, comprising delivering a plasmid encoding a codon-optimized B. anthracis antigen as described above. The invention is also directed to pharmaceutical compositions comprising plasmids encoding a codon-optimized B. anthracis antigen as described above, and further comprising adjuvants, excipients, or immune modulators.

The invention discloses a method for detecting bacillus anthracis by combining RPA with a CRISPR technology and a complete set of reagents. The invention provides a complete set of primer group for detecting the bacillus anthracis and / or screening bacillus anthracis virulent strains. The complete set of primer group contains three sets of primers specific to chromosome genes BA_5345 and plasmid virulent genes pagA and capA of the bacillus anthracis virulent strains; each set of primer is composed of an RPA primer and crRNA; the RPA primer is designed according to a target gene conserved sequence; the crRNA comprises an anchoring sequence capable of being combined with cas protein and a spacer sequence matched with an RPA primer amplification product sequence. The complete set of primer group has relatively good sensitivity and specificity for sample detection of clinical simulation samples and soil simulation samples, can effectively distinguish the bacillus anthracis virulent strainsfrom other bacteria, provides a rapid detection method for bacillus anthracis in-vitro diagnosis, and has important significance for soil environment screening of the bacillus anthracis in Chinese epidemic areas.

The invention provides bacteriophages that infect Bacillus bacteria, including Bacillus anthracis, and compositions containing the bacteriophages. The invention also provides methods for using the bacteriophages of the invention to detect, prevent and treat infection of an organism by Bacillus bacteria. Methods and materials to decontaminate a surface or an organism that is contaminated with Bacillus bacteria or Bacillus spores are also provided.

The present invention relates generally to methods and materials relating to newly characterised enzymes from Pusillimonas noertemannii, or variants thereof, capable degrading poly-γ-D-glutamic acid, for example as is present in the capsule of B. anthracis. Such depolymerases have utility as therapeutics.

The present invention relates to peptides that bind to the bacterial spores, such as B. anthracis, B. subtilis and B. cereus spores. The present invention also relates to method of identifying such peptides using phage display ligand screening system. The present invention further relates to the use of such peptides for the detection of bacterial spores, such as Bacillus anthracis spores.

The inventive subject matter relates to a competitive method for estimating the concentration in a sample of a Bacillus anthracis protein or antibody thereof selected from the group consisting of protective antigen (PA), lethal factor (LF) and edema factor (EF). The method may employ the use of Fluorescence Polarization, FLT or FRET. The competitive methods are capable of detecting a target protein within 5 minutes within the range of 0.1 to 10.0 nM. The methods provide for the rapid detection and quantitation of bacteria, bacterial antigen or antibody in culture media or broth of growing cultures of bacteria, including B. anthracis by fluorescent methods.

Method for hyper-spectral imaging and analysis of a sample of matter, for identifying and characterizing an object of interest therein. Preparing test solution or suspension of the sample, including adding thereto a spectral marker specific to object of interest, such that if object of interest is in test solution or suspension, object of interest becomes a hyper-spectrally active target which is hyper spectrally detectable and identifiable; adding to test solution or suspension a background reducing chemical, for reducing background interfering effects caused by presence of objects of non-interest in test solution or suspension, thereby increasing hyper spectral detectability of hyper spectrally active target in test solution or suspension; generating and collecting hyper-spectral image data and information of test solution or suspension; and, processing and analyzing thereof. Exemplary objects of interest are biological agents—bacteria (Bacillus anthracis), viruses, fungi, toxins, or, chemical agents—nerve agents (sarin, tabun, soman), and chemical poisons.

The invention relates to the technical field of biology, and specifically discloses recombinase polymerase amplification (RPA) primers and a method used for detecting bacillus anthracis. According tothe RPA primers used for detecting the bacillus anthracis, 1 pair of RPA primers are designed and synthesized on basis of a conservative sequence of a bacillus anthracis BA5345 gene; and the RPA primers are shown as SEQ ID NO. 1-2. Subjected to further optimization on primer concentration, reaction temperature and reaction time, the bacillus anthracis can be specifically detected after addition of2.0 microliters of the upstream primer and the downstream primer, of which the concentration is 10 mmol / L, into 50 microliters of a RPA reaction system and subsequent constant-temperature reaction ina water bath pot at 39 DEG C for 30 minutes; and more RPA amplification products can be obtained. Thus, the RPA detection method developed by the invention has an sensitivity which is 100 times higher than sensitivities of conventional PCR methods, as well as a positive detection rate of clinical samples of contaminated fur up to 65.71% which is significantly higher than positive detection rate of the conventional PCR methods. The RPA method established by the invention is easy to operate, fast to react, as well as true and reliable in results; and thus, the RPA method is suitable for rapid detection of the bacillus anthracis.

The compositions and methods described herein disclose the design, synthesis and testing of compounds that act as inhibitors of DHFR. The basic scaffold of these inhibitors includes a 2,4-diaminopyrimidine ring with a propargyl linker to another substituted aryl, bicyclo or heteroaryl ring. These DHFR inhibitors are potent and selective for many different pathogenic organisms, including the DHFR enzyme from bacteria such as Bacillus anthracis and methicillin-resistant Staphylococcus aureus, fungi such as Candida glabrata, Candida albicans and Cryptococcus neoformans and protozoa such as Cryptosporidium hominis and Toxoplasma gondii. These compounds and other similar compounds are also potent against the mammalian enzyme and may be useful as anti-cancer therapeutics.

Method for hyper-spectral imaging and analysis of a sample of matter, for identifying and characterizing an object of interest therein. Preparing test solution or suspension of the sample, including adding thereto a spectral marker specific to object of interest, such that if object of interest is in test solution or suspension, object of interest becomes a hyper-spectrally active target which is hyper-spectrally detectable and identifiable; adding to test solution or suspension a background reducing chemical, for reducing background interfering effects caused by presence of objects of non-interest in test solution or suspension, thereby increasing hyper-spectral detectability of hyper-spectrally active target in test solution or suspension; generating and collecting hyper-spectral image data and information of test solution or suspension; and, processing and analyzing thereof. Exemplary objects of interest are biological agents—bacteria (Bacillus anthracis), viruses, fungi, toxins, or, chemical agents—nerve agents (sarin, tabun, soman), and chemical poisons.

The invention discloses a method for expressing anthrax bacteria gamma bacteriophage lysins. The invention connects an anthrax bacteria bacteriophage gene and pMEX9K, by adopting a pichia pastoris expression system and an expression vector pMEX9K (ZL02117906.9) with intellectual property right, to construct a new expression plasmid pMEXplyG; reservoir host Pichia pastoris GS115 undergoes electrotransformation after linearization; a producing strain G6 is obtained after random selection and pressure filtering, so that the gamma bacteriophage lysins are expressed in pichia pastoris G6 supernatant, and a expression product does not contain superfluous amino acid; and the gamma bacteriophage lysins with the purity of over 95 percent are obtained after centrifuging, ultrafiltering, ion-exchange chromatography, dewatering chromatography and gel chromatography. The anthrax bacteria gamma bacteriophage lysins have cleavage activity to anthrax bacteria and fungus gemma in sprouting, and can be used to develop anthrax decontaminating agents and anthrax medicines.

The invention discloses a skin antibacterial liquid. The skin antibacterial liquid comprises the following raw materials in parts by weight, 16.13-3.22 parts of perfoliote knotweed herb, 5.33-1.06 parts of baical skullcap root, 5.38-1.09 parts of coptis root, 6.45-1.29 parts of amur corktree bark, 10.75-2.15 parts of astragalus root, 3.23-0.65 parts of divaricate saposhnikovia root, 2.15-0.43 parts of Artemisia argyi, 1.09-0.22 parts of Eucalyptus, 4.3-0.86 parts of honeysuckle, 3.23-0.65 parts of licorice and 1.09-0.22 parts of borneol. Through the mutual effect of pure traditional Chinese medicine extraction and excellent formula traditional Chinese medicinal materials, the traditional Chinese medicine composition has obvious curative effects on burns and scalds, skin ulcer, acne, urticaria, herpes zoster, eczema, pustule and the like, and also has multiple curative effects on more than thirty skin diseases such as prickly heat, Hong Kong feet, skin itch and allergic skin diseases; the traditional Chinese medicine composition can be used for preventing a patient from being repeatedly infected by bacteria and conveniently solving the skin problem of the patient, has different degrees of bacteriostatic action on staphylococcus aureus, diplococcus pneumoniae, streptococcus deep haemolyticus, corynebacterium diphtheriae, pseudomonas aeruginosa and bacillus anthracis, effectivelyimproves the effects of sterilization, bacteriostasis, inflammation resistance and allergy resistance, improves the treatment effect and is convenient to use.

This invention discloses Bacillus anthracis gamma-phase lyase epitope, its lyase mutant and application. This invention provides the epitope of Bacillus anthracis gamma-phase lyase PlyG, and mutant lyase MPlyG. The epitope is 164th-172nd amino acid residues of lyase PlyG, and is shown in SEQ ID No.4. Mutant lyase MPlyG is derived from lyase PlyG by deleting one or more of 164th-172nd amino acid residues. Animal experiments show that compared with PlyG, MPlyG has lower antigenicity, lower immunogenicity, and similar lyase activity. Therefore, MPlyG can be used to prevent and treat charbon and manufacture corresponding drugs.

The present invention relates to methods and compositions for stimulating an immune response. Specifically, the present invention provides methods of inducing an immune response to bacteria of the genus Bacillus (e.g., Bacillus anthracis) in a subject (e.g., a human subject) and compositions useful in such methods (e.g., a nanoemulsion comprising Bacillus anthracis or an immunogenic portion thereof). Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., vaccination) and research applications.

The present invention relates to the field of bacterial Surface (S)-layer proteins, in particular to compounds capable of disrupting the bacterial S-Layer, specifically the S-Layer of Bacillus anthracis. More particularly, the invention provides for single domain antibodies for diagnosis and treatment of infection caused by pathogens with an S-Layer, in particular of Bacillus anthracis infection. The invention relates to S-Layer protein binding agents inhibiting bacterial growth and interrupting S-Layer assembly, useful in the treatment of bacterial infection, more specifically treatment of anthrax disease.

The invention discloses a method and a complete set of reagents for detecting Bacillus anthracis with RPA combined with CRISPR technology. The present invention provides a set of primers for detecting Bacillus anthracis and / or screening virulent strains of Bacillus anthracis, including three sets of primers specific to the chromosomal gene BA_5345 of the virulent strain of Bacillus anthracis, the plasmid virulence genes pagA and capA, Each set of primers is composed of RPA primers and crRNA, and the RPA primers are designed according to the conserved sequence of the target gene, and the crRNA includes an anchor sequence capable of binding to the cas protein and a spacer sequence matching the sequence of the amplification product of the RPA primer. The complete primer set of the present invention has good sensitivity and specificity for detection of clinical simulation samples and soil simulation samples, can effectively distinguish virulent strains of Bacillus anthracis from other bacteria, and provides a rapid detection method for in vitro diagnosis of Bacillus anthracis. Soil environmental screening of Bacillus anthracis in epidemic areas in China is of great significance.

The invention discloses a Lactobacillus rhamnosus and its application in the preparation of bacteriocins. The preserved taxonomic name of the Lactobacillus rhamnosus is: Lactobacillus rhamnosus ( Lactobacillus rhamnosus ) zrx01; deposited in the General Microbiology Center of China Committee for the Collection of Microorganisms; date of preservation: December 22, 2017; preservation number is CGMCC No.15076. The bacteriocin produced by Lactobacillus rhamnosus zrx01 screened by the present invention can inhibit a variety of harmful bacteria, especially for Gram-positive bacteria Staphylococcus aureus, Listeria monocytogenes, Bacillus anthracis, Gram-negative bacteria large intestine Bacillus, Campylobacter jejuni, and Alicyclobacillus acidterreus have strong inhibitory effects, but they have no inhibitory effect on probiotics such as Lactobacillus plantarum and Lactobacillus acidophilus. Same non-inhibitory.

The present invention relates to methods and compositions for using nucleotide sequence variations of 16S and 23S rRNA within the B. cereus group to discriminate a highly infectious bacterium B. anthracis from closely related microorganisms. Sequence variations in the 16S and 23S rRNA of the B. cereus subgroup including B. anthracis are utilized to construct an array that can detect these sequence variations through selective hybridizations and discriminate B. cereus group that includes B. anthracis. Discrimination of single base differences in rRNA was achieved with a microchip during analysis of B. cereus group isolates from both single and in mixed samples, as well as identification of polymorphic sites. Successful use of a microchip to determine the appropriate subgroup classification using eight reference microorganisms from the B. cereus group as a study set, was demonstrated.